Animal models of right heart failure
Andersen, Asger; van der Feen, Diederik E.; Andersen, Stine; Schultz, Jacob Gammelgaard; Hansmann, Georg; Bogaard, Harm Jan
Published in:
Cardiovascular diagnosis and therapy

DOI:
10.21037/cdt-20-400

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment.

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Animal models of right heart failure

Asger Andersen¹, Diederik E. van der Feen², Stine Andersen¹, Jacob Gammelgaard Schultz¹, Georg Hansmann¹, Harm Jan Bogaard¹

¹Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark; ²Center for Congenital Heart Diseases, University Medical Center Groningen, Groningen, The Netherlands; ³Department of Pediatric Cardiology and Critical Care, Hannover Medical School, Hannover, Germany; ⁴Amsterdam UMC, Vrije Universiteit Amsterdam, Pulmonary Medicine, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands

Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: None; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Asger Andersen, Department of Cardiology, Aarhus University Hospital, Palle Juul Jensens Boulevard 99, 8200 Aarhus, Denmark. Email: asger.andersen@clin.au.dk.

Abstract: Right heart failure may be the ultimate cause of death in patients with acute or chronic pulmonary hypertension (PH). As PH is often secondary to other cardiovascular diseases, the treatment goal is to target the underlying disease. We do however know, that right heart failure is an independent risk factor, and therefore, treatments that improve right heart function may improve morbidity and mortality in patients with PH. There are no therapies that directly target and support the failing right heart and translation from therapies that improve left heart failure have been unsuccessful, with the exception of mineralocorticoid receptor antagonists. To understand the underlying pathophysiology of right heart failure and to aid in the development of new treatments we need solid animal models that mimic the pathophysiology of human disease. There are several available animal models of acute and chronic PH. They range from flow induced to pressure overload induced right heart failure and have been introduced in both small and large animals. When initiating new pre-clinical or basic research studies it is key to choose the right animal model to ensure successful translation to the clinical setting. Selecting the right animal model for the right study is hence important, but may be difficult due to the plethora of different models and local availability. In this review we provide an overview of the available animal models of acute and chronic right heart failure and discuss the strengths and limitations of the different models.

Keywords: Pulmonary hypertension (PH); animal models; pulmonary heart disease; congenital heart defects; pulmonary embolism (PE)


doi: 10.21037/cdt-20-400

View this article at: http://dx.doi.org/10.21037/cdt-20-400

Introduction

The right ventricle is a thin-walled structure and an increase in RV afterload, sudden or chronic, may induce RV failure. RV failure is the ultimate cause of morbidity and mortality in several cardiovascular conditions such as congenital heart disease, left heart disease, pulmonary hypertension (PH), pulmonary valve disease, and acute pulmonary embolism (PE) (1,2). There are no current therapies that directly target or support the failing RV. There have been several attempts to develop therapies that directly support the failing RV, but the clinical translation has so far been unsuccessful and treatments that effectively improve the failing left heart do not seem to support the failing RV (3). As RV failure is often secondary to other cardiovascular conditions, the primary treatment goal is to treat the cause of RV failure. We know that RV function is an independent risk factor in many cardiopulmonary morbidities (4) and therefore, targeted therapy to improve RV function may improve overall morbidity and mortality in patients.
suffering from RV failure. To test current and new therapies and to conduct basic research for better understanding of the underlying pathophysiology in RV failure, we need solid and well-described animal models of RV failure. A plethora of animal models of RV failure exists and choosing the right model for the right experiment may be challenging. The aim of this review is to give an overview of the available models of RV failure and to provide the reader with strengths and limitations of the existing RV failure models.

**Animal models of RV failure**

RV failure can be caused by several entities. Figure 1 gives an overview of the targets for inducing RV failure in animal models. The different methods will be discussed in the following sections, and for each section there is a table with the animal models listed including strengths and limitations to the model and references to the animal species that the model have been introduced in.

**Acute RV failure**

The thin-walled RV is sensitive to acute increases in afterload. This causes acute RV failure induced by an abrupt increase in RV afterload in the majority of experimental models. Beside this common denominator, models of acute RV failure vary both in terms of the method of afterload increase, animal species, and hemodynamic phenotype. We focus on two main categories; Models of acute PE and models of acute transient pulmonary occlusion (Table 1).

**Models of acute PE**

Models of acute PE inject different materials to the pulmonary circulation, hereby increasing pulmonary vascular resistance (PVR) and hence RV afterload and strain.

**Pharmacological PE models**

Pharmacological PE models use intravascular injections of drugs which cause blood coagulation and/or vasoconstriction. Most frequently used are thrombin (5), collagen combined with epinephrine (6), or adenosine diphosphate (10). To target the pulmonary circulation, drugs are injected in the jugular vein, the right heart, or directly into the pulmonary circulation. The latter models are more specific, but require right heart catheterization. These models are mainly used in rodents and the hemodynamic phenotype is often complete hemodynamic collapse and death within minutes of injection (6). The primary endpoint is often mortality, as hemodynamic efficacy is difficult to detect due to the massive thrombus burden. The models are simple and inexpensive, but require a high number of animals (49). More recent models have succeeded in creating a balanced phenotype of RV strain (7-9). Despite this, the pathophysiology of the models remains far from that of clinical PE.

**Artificial exogenous PE models**

Models of exogenous PE inject pre-formed thrombus material into the pulmonary circulation. The majority are based on artificial thrombus material such as glass beads or plastic spheres (11-20,50-52). While non-physiological, these models create a predictable increase in PVR and RV strain. Furthermore, the afterload is consistent over time, as the materiel does not dissolve. The hemodynamic phenotypes vary from little or no RV strain to decompensated RV failure and shock depending on the afterload increase. Exogenous clot models are therefore
Table 1 Models of acute right ventricular failure

<table>
<thead>
<tr>
<th>Method</th>
<th>Strengths</th>
<th>Limitations</th>
<th>Mouse</th>
<th>Rat</th>
<th>Rabbit</th>
<th>Dog</th>
<th>Sheep</th>
<th>Pig</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pulmonary embolism</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmacological coagulation</td>
<td>Feasible</td>
<td>Often fatal</td>
<td>(5-9)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>vasoconstriction</td>
<td>Minimal instrumentation</td>
<td>Difficult to control thrombus load</td>
<td>(10)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exogenous clot</td>
<td>Feasible</td>
<td>Unlikely human physiology</td>
<td>(11-13)</td>
<td></td>
<td>(14,15)</td>
<td>(16)</td>
<td>(17,18)</td>
<td>(19,20)</td>
</tr>
<tr>
<td>Artificial</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exogenous clot</td>
<td>Comparable to human physiology</td>
<td>Thrombus created \textit{ex vivo}—Homogenous and fresh</td>
<td>(21-24)</td>
<td></td>
<td>(25-30)</td>
<td>(18,31)</td>
<td>(32-37)</td>
<td></td>
</tr>
<tr>
<td>Autologous</td>
<td>Thrombus resolution possible</td>
<td>Difficult to administer en block—Risk of fragmentation.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deep venous thrombosis</td>
<td></td>
<td></td>
<td>(38)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary artery occlusion</td>
<td></td>
<td></td>
<td>(39)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary artery banding</td>
<td>Precise afterload increase</td>
<td>Need for open chest</td>
<td>(40)</td>
<td></td>
<td>(41)</td>
<td>(42)</td>
<td>(43-45)</td>
<td>(46,47)</td>
</tr>
<tr>
<td>Stable afterload</td>
<td>Not suited for pulmonary interventions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjustable</td>
<td>Unlikely human physiology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wide range of RV strain</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary artery balloon</td>
<td>Precise afterload increase</td>
<td>Not suited for pulmonary interventions</td>
<td>(48)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stable afterload</td>
<td>Unlikely human physiology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjustable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wide range of RV strain</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

An overview of models of RV failure stratified to method of afterload increase and animal species.

well-suited for evaluating RV function and interventions targeting the RV or systemic circulation. The concept has been implemented in a wide range of species varying from rodents to large animals. The artificial nature of the thrombus, however, differs from that of autologous PE. Firstly, artificial material does not possess the same vasoactive effects as an autologous thrombus. Secondly, the artificial materiel cannot be dissolved and does not allow for evaluations of interventions of thrombus removal.

**Autologous exogenous PE models**
Models of autologous PE all use a variation of the same technique. Blood is drawn from the animal, then set to coagulate \textit{ex vivo} into an autologous thrombus, before it is re-injected to the pulmonary circulation as a PE. The protocol for thrombus formation varies between
models. While all models aim to create a PE similar to that found in patients, thrombi are still created *ex vivo*, and are not exposed to the continuous flow of substrates in the vein of a patient. The thrombi are therefore less heterogeneous, less rigid, and less fibrotic compared with a chronic thrombus from a patient (53). The thrombus size varies between models from small clots, which lodge distally (25,26,31-36,54), to large central PEs (37). The hemodynamic phenotype entails ranges of RV strain (37,54) and decompensated RV failure (21-23). Models of autologous PE are well-suited for studies of RV function, but also of interventions focusing on the thrombus, both pharmacological treatments and, in the larger animal models (dog, sheep, pig), novel catheter directed therapies. The latter may prove important in preclinical evaluations of safety and efficacy in this promising new field (55).

**Deep venous thrombosis-PE models**

The models most true to that of clinical PE are based on *in vivo* thrombus formation. By occluding the inferior vena cava, models have succeeded in creating deep vein thrombosis (DVT), which can be released to travel via the blood stream to the pulmonary circulation (39). As the thrombus forms *in vivo*, over time, it is more heterogeneous and possibly more similar to that of a patient. The models are however associated with challenges. Instrumentation is more extensive and the DVT needs days to form, why experiments cannot be performed on the same day. Furthermore, it is not possible to control the thrombus size and hence the afterload increase and hemodynamic phenotype. Consequently, models have not been able to show RV strain. Studies on experimental DVT-PE are few and have to our knowledge only been implemented in rats (38) and pigs (39).

**Models of transient pulmonary artery occlusion**

Models of transient pulmonary artery occlusion increase RV afterload by mechanical constriction of the pulmonary artery from the exterior or by inflation of intravascular balloons (48). External occlusion can be applied by ligature (43,44), snares (42), simple banding (40), or more advanced adjustable bands using air (41,45,46). The occlusion, and hence the PVR and RV strain, can be adjusted very precisely and, as opposed to PE models, the resistance can be reduced or even removed as the occlusion can be re-loosened. As the mechanical occlusion is fixed at the level of the main pulmonary artery, the resistance of the more distal pulmonary circulation is less important. The models are therefore well-suited for studies of isolated RV function and not of pulmonary effects. A drawback of the models is the need for open chest protocols, which both increases instrumentation but also changes cardiovascular hemodynamics. Models exists in both rodents (40), rabbits (41), and large animals (42-45).

**Sustained pressure overload-induced RV failure**

Sustained pressure overload of the RV can induce failure. The right ventricle does not respond well to an abrupt increase in afterload (56) but with a chronic pressure overload the RV adapts well and it can adapt to systemic afterload for an extended period of time. Initially, the adaption to the increase in pressure is beneficial, but with sustained and increasing pressure overload, the RV will eventually fail (57). Sustained pressure overload of the RV is clinically seen in patients with PH and a RV outflow tract or pulmonary valve stenosis. In animal models, it is important to distinguish between models with a fixated RV afterload or not. The pulmonary artery banding model is a model with a fixated afterload making it suitable to evaluate interventions targeting RV function without worrying about the result being secondary to afterload reduction. Models of PH on the other hand are very well suited to evaluate treatments targeting the pulmonary circulation, but an improvement in RV function may be secondary to an afterload reduction and not caused by direct effects on the RV. The models are presented in the following and Table 2.

**Pulmonary artery banding (PAB)**

PAB is a simple surgical procedure, where a band is tightened around the pulmonary artery to increase afterload. This induces sustained pressure overload and over time RV dysfunction and/or failure. In small animal models of rats and mice the most commonly used methods is a pre-adjusted hemostatic clip (58,61-63) or a ligature tightened around the pulmonary artery (59,60,64-66,96,97). Both methods works well, but the clip-method may be a bit faster to learn and more reproducible, whereas the ligature method does not introduce metal, making it more suitable for MRI or ultrasound evaluation of flow in the pulmonary artery. A challenge with the banding model have been to introduce RV failure and not just a well-adapted hypertrophic RV (98). The challenge is that in adult animals a tight band induces acute RV failure and death, but a looser band will never induce RV failure, but only compensated RV hypertrophy. To overcome this, most models introduce
<table>
<thead>
<tr>
<th>Method</th>
<th>Strengths</th>
<th>Limitations</th>
<th>Mouse</th>
<th>Rat</th>
<th>Rabbit</th>
<th>Dog</th>
<th>Sheep</th>
<th>Pig</th>
<th>Calves</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary artery occlusion</td>
<td></td>
<td>Abrupt initial afterload increase</td>
<td>(58-60)</td>
<td>(61-66)</td>
<td>(67-69)</td>
<td>(70-72)</td>
<td>(73)</td>
<td>(74-76)</td>
<td></td>
</tr>
<tr>
<td>Pulmonary artery banding</td>
<td>Simple</td>
<td>Reproducible</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Difficult to induce severe RV failure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Direct RV affection</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary hypertension</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monocrotaline</td>
<td>Feasible</td>
<td>Myocarditis, large variation</td>
<td>(77-79)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Simple</td>
<td>No angio-obliterative pulmonary lesions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monocrotaline + hypoxia</td>
<td>Angio-obliterative pulmonary lesions</td>
<td>Myocarditis</td>
<td>(80)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Decompensated RV failure</td>
<td>Large same-strain animal variation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monocrotaline + pneumonectomy</td>
<td>Angio-obliterative pulmonary lesions</td>
<td>Myocarditis</td>
<td>(81)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Decompensated RV failure</td>
<td>Large same-strain animal variation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Surgical procedure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic hypoxia</td>
<td>Stable response within same-strain animals</td>
<td>Only compensated RV hypertrophy</td>
<td>(82)</td>
<td>(83)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(84)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Spontaneously reversible after return to normoxia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sugen+hypoxia</td>
<td>Decompensated RV failure</td>
<td>Possible Off-target effects of Sugen and/or hypoxia</td>
<td>(85)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(86,87)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fawn-hooded rats</td>
<td>Chromosomal abnormality similar to idiopathic PAH</td>
<td>Limited to the fawn-hooded rat</td>
<td>(88-90)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sugen in athymic rats</td>
<td>Lung pathophysiology comparable to human PAH</td>
<td>Development of RV failure has not been described</td>
<td>(91)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Apoptosis of myocardial microvascular endothelial cells</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic thromboembolic pulmonary hypertension (CTEPH)</td>
<td>Mimics the hemodynamics of CTEPH</td>
<td>Not exact pathophysiological CTEPH</td>
<td>(92)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(93-95)</td>
</tr>
</tbody>
</table>

An overview of models of RV failure stratified to method of afterload increase and animal species. PAH, pulmonary arterial hypertension; CTEPH, chronic thromboembolic pulmonary hypertension.
the surgery in weanlings. By doing this, the stenosis will become relatively more severe as the animal grows and allow for severe RV failure over time.

Another advantage of the banding method is that the precise diameter of the band/clip allows for precise titration of afterload to induce RV hypertrophy, compensated RV failure, or decompensated RV failure (61,99,100). As seen by hypertrophy with preserved hemodynamics, altered hemodynamics, but no extracardiac signs of RV failure, and altered hemodynamics with extracardiac signs of RV failure. The larger animal models of PAB have been described in rabbits (67-69), dogs (70-72), swine (74,75), and sheep (44,101). Advantage of large animal models over small animal models in RV failure is predominantly the more “human like” anatomy of the larger animals making more refined surgical methods for banding possible. This allows for bands that can be adjusted (73,75,102,103) over time, an obstructing balloon instead of a band (104), and removal of band to investigate reverse RV remodeling (71).

Hypoxia

Chronic hypoxia (usually FiO₂ 10% or 0.5 atmospheric pressure, for 3 weeks) has been used to induce PH in various animal species for decades (82-84). Exposure to hypoxia cause transient muscularization and thickening of the smaller pulmonary arteries (105) accompanied by an inflammatory response (106). RV function is, however, well preserved under hypoxic conditions (107).

PH caused by chronic hypoxia (group 3.4 PH “hypoxia without lung disease”) (108) only induces compensated RV hypertrophy, but no RV dilation, and is transient, i.e., RV and PA pressure, and peripheral PA muscularization turn back to normal within days when animals are returned to room air. Accordingly, the chronic hypoxia model is not a model of RV dysfunction or failure, and not a model of PAH.

The response to chronic hypoxia varies significantly with age, where younger animals with more immature lungs seems much more susceptible to develop severe vascular injuries (84). The response also varies among species, where rats develop more severe PH when exposed to hypoxia compared with for example mice (105). The most severe response is observed in Fawn-hooded rats (88). Due to defect pulmonary vascular oxygen sensing, they develop severe PH under hypoxic conditions and even under normoxic conditions changes in pulmonary pressures occurs in these rats (89,90).

Specific genetic animal models may yield protection or aggravation of chronic hypoxia-induced PH, and thus chronic hypoxia may be used in the phenotyping of such genetic models (109).

However, the aforementioned normalization of PH and pulmonary vascular remodeling after the end of chronic hypoxia, and the limited food and fluid intake during hypoxia (dehydration) are major limitation to the chronic hypoxia model. It should also be noted that chronic hypoxia drastically changes the mRNA expression profile in rat RV even several weeks after the return to normoxia (110), highlighting that rodent models involving hypoxia, i.e., chronic hypoxia-mediated PH or Sugen-Hypoxia (SuHx-PAH; see below under 2.2.4), should include a vehicle-chronic hypoxia control group (110).

Monocrotaline (MCT) in rats

In the 1960s, it was shown that ingestion of the Crotalaria spectabilis seeds (MCT) induced PH in rats (77). Today, a subcutaneous injection of 60 mg/kg is the most common way to administer MCT (78). After oxidization in the liver to its active metabolite, MCT induces pulmonary endothelial cell damage and vasculitis (111), and during the following weeks PH and associated RV hypertrophy and failure develop.

Its methodological simplicity and low cost compared with other PH models makes the MCT model an appealing model, but its translatability is very limited. In addition to pulmonary effects, MCT also causes myocarditis evident by infiltration of inflammatory cells in the RV and LV myocardium (112,113). These direct cardiac effects are a major limitation when the model is used in RV failure research.

Others questioned the suitability of the MCT model as a preclinical model of pulmonary arterial hypertension (PAH) based on the absence of plexiform lesions and occurrence of pulmonary venous changes (105). On the contrary, angio-obliterative pulmonary lesions develop in MCT rats with increased right pulmonary blood flow after left pneumonectomy and in MCT rats subjected to hypoxia, and these 2-hit-models may provide better alternatives to the single-hit MCT model (80,81).

Sugen hypoxia (SuHx) in rats

The SuHx rat model is a 2-hit model, where a single subcutaneous injection with the VEGF-receptor antagonist Sugen 5416 is followed by 3–4 weeks of hypoxia (86). The resulting endothelial hyperproliferation leads to progressive pulmonary vascular occlusion even after return to normoxia
and RV systolic pressures of approximately 75 (65–100 mmHg) (87,114,115).

Severe PH is confirmed 1 week after return to normoxia, in the absence of significant RV dysfunction, but then systolic and diastolic RV dysfunction develops and RV failure is evident after another 5 weeks (6 weeks after the end of 3 weeks hypoxia) (110). A linear relationship between RV systolic pressure/RV hypertrophy and the density of occluded pulmonary vessels confirms, that the development of increased RV pressures and RV hypertrophy in this model is indeed caused by the pulmonary vascular changes and not direct cardiac effects of Sugen 5416 and/or hypoxia (116). Compared with rats exposed to hypoxia alone, SuHx rats develop decompensated RV failure (elevated RVEDP, RV dilation and decreased RVEF by cardiac MRI) (110) with maladaptive RV remodeling. Moreover pulmonary vascular lesions (concentric hypertrophic and plexiform) have been reported in this model (86,110,117), and accordingly the SuHx model is generally considered the rat model resembling human PAH and associated RV failure the best (114,118). Another approach that resembles the changes seen in SuHx is pneumonecrtomy in combination with sufgen 5416 (119). This raises the question on whether the changes in the SuHx model are caused by hypoxia alone or if they are induced by the increase in shear- and radial stress secondary to hypoxic vasoconstriction.

Sugen normoxia in athymic rats
Athymic nude rats lacking T cells develop PH and associated RV hypertrophy after subcutaneous Sugen 5416 injection (10–20 mg/kg/body weight) even without exposure to hypoxia, although RV (dys) function has not been assessed in this model (91). Preliminary experimental work indicates that these rats rapidly develop RV failure, as assessed by echocardiography and cardiac MRI, associated with high mortality (G. Hansmann, unpublished observation).

The lack of T regulatory cells and the surge of leukotriens have been proposed as major drivers of the pathobiology in the athymic SuNx rat model and (91) the model have been used to prove the involvement of macrophage derived leukotriene A4 hydrolase in the development of PH (120).

Sugen hypoxia in mice
Weekly Sugen 5416 injections during exposure to hypoxia cause PH in mice, but despite persistent PH, progressive RV failure and pulmonary occlusive lesions are lacking during long-term follow-up (85,121), and a reliable wild type murine model resembling the progressive development of pulmonary vascular lesions and RV failure in PAH patients still needs to be established.

A recent systematic review of animal models of PH including almost 300 publications recapitulated that the chronic hypoxia model is characterized by the lowest increase in RV systolic pressure and hypertrophy compared with the other models (122). The most severe response occurs in the SuHx model. Comparing MCT and SuHx rats, MCT rats have a much higher mortality despite similar degrees of RV dysfunction and lower mPAP in the MCT rats, suggesting that other factors contribute to disease progression and death in the MCT model (78). Although the response to chronic hypoxia varies significantly across species, it is consistent within a selected animal strain. For example the response to hypoxia is much more pronounced in rats compared with mice (122). On the contrary, the response to MCT injection varies significantly among even same-strain animals, probably due to differences in hepatic metabolism (82,105).

Chronic thromboembolic PH (CTEPH)
CTEPH is a disease that develops from unresolved acute PE or in situ thrombus formation that obstruct the pulmonary vessels (123). The severity of disease is not only dependent on the mechanical obstruction of the chronic clots but also of the small vessel disease that follows (124,125).

The underlying pathophysiology is not fully understood, and the causes of CTEPH seems to be multifactorial. Repeated thromboembolic events, coagulopathies, and inflammation all seem to be involved in the development of CTEPH (126). The lack of pathobiological understanding of CTEPH makes the available animal models limited, but it also underlines the importance of developing new animal models, as they can improve our understanding of this disease. Several attempts have been made to develop a model of CTEPH, but the early models did not succeed in replicating CTEPH due to clot lysis or the absence of PH and RV failure despite inhibition of clot lysis and the presence of chronic thrombi (127-130). Newer models have succeeded in mimicking the hemodynamic characteristics of CTEPH. One model of CTEPH ligate the left pulmonary artery followed by weekly injection of histoacryl in the artery of the right lower lobe for 5 weeks (93). Another model induces a percutaneously placed cobber scaffold followed by embolization and tranexamic acid (94). Despite successful mimicking the hemodynamics of CTEPH, they do not mimic the pathophysiology or -biology of CTEPH.
Rat and pig models of microspheres in combination with thrombin, the tyrosine kinase inhibitor SU5416, or nitric oxide synthase (NOS) inhibition induced PH, RV hypertrophy, and thickening of the pulmonary arteries suggesting more accurate CTEPH models, but a limitation in these models is the use of microbeads, not autologous blood clots (92,95). The available CTEPH models are very useful for describing pathophysiology changes with increasing RV afterload to investigate interventions that may limit microvascular disease, and the researchers should be complemented for developing these elaborate models, but to fully understand the underlying pathophysiology and -biology of CTEPH we need more animal models that truly mimics CTEPH.

**Volume overload-induced RV failure**

RV volume overload occurs in three main clinical entities: (I) pulmonary regurgitation due to pulmonary valve insufficiency or as occurs frequently in repaired Tetralogy of Fallot (ToF) (131,132); (II) tricuspid regurgitation (133); (III) pre-tricuspid shunts such as atrial septal defects (ASDs). Post-tricuspid shunts such as ventricular septal defects (VSDs) also cause RV volume overload, but with an increased pressure load component due to high LV systolic pressures and the relatively rapid development of shunt-induced PAH (134). Volume overload-associated RV failure is a growing concern especially in repaired ToF, now survival of these patients throughout childhood has improved (132). However, the pathology of RV volume load and its treatment are relatively unexplored area of research, and experimental data in animal models is warranted (135).

The available animal models for RV volume overload are (I) the aorto-caval shunt model, and (II) the pulmonary regurgitation model. A model for tricuspid regurgitation has also been described in dogs, but RV volume load was not assessed (136) (Table 3).

**Aorto-caval shunt**

The aorto-caval shunt model has been described in mice (153), rats (137,138,144,153,154), pigs (155), and dogs (152). The rat is the predominant species. Shunt surgery in rats is a relatively simple and quick (20 minutes) procedure, of which a detailed step-by-step protocol and a video are available (139). In a meta-analysis of 145 shunted animals of multiple species, aorto-caval shunt surgery consistently led to increased end-diastolic and end-systolic volume and area, increased cardiac output, and stroke volume, indicating volume load. RV dP/dt max also increased, indicating increased contractility, probably due to the Frank-Starling mechanism (135). TAPSE and RV ejection fraction did not differ in shunted animals versus controls, and also did not deteriorate over time (up to 90 days), suggesting that RV failure does not occur in shunted animals. However, meta-regression analysis did indicate that the early rise in cardiac output as a result of the shunt decreases after 90 days, suggesting a trend towards RV dysfunction. RV end diastolic pressure, a surrogate for RV dysfunction also increased in shunted animals versus controls. RV hypertrophy was observed in all shunted animals, and was consistently reported as an early response phenomenon, with no progression during prolonged shunting. Myocardial fibrosis was only observed in shunted animals after 90 days (135). When using the aorto-caval shunt model to study isolated RV volume overload, it is important to realize that these models may also induce PH (thus RV pressure load) over time, due to chronic pulmonary overcirculation (156). The addition of a pressure component to RV load is associated with a distinctly different hemodynamic and molecular RV adaptation profile (137). It is advisable therefore to rule out the presence of PH by measuring pulmonary artery pressures.

**Pulmonary valve regurgitation**

The pulmonary regurgitation, or pulmonary valve insufficiency model has been characterized predominantly in pigs (76,157-162), but also in sheep (163) and mice (164). Pulmonary regurgitation is created by placing sutures through the wall of the pulmonary trunk around the hinge points of the pulmonary valve leaflets (157). In a meta-analysis of 135 animals, pigs mostly, pulmonary regurgitation surgery led to increased end-diastolic and end-systolic volume and area, indicating RV volume load (135). RV stroke volume was also increased, but cardiac output and ejection fraction were unchanged. Pulmonary regurgitation fraction was increased. RV contractility, expressed as RV preload recruitable stroke work (PRSW) and RV end-systolic pressure-volume relation (ESPVR), were significantly decreased, and RV end-diastolic pressure was increased in regurgitation animals compared to controls, suggesting RV dysfunction. Like in the shunted animals, RV hypertrophy was observed early (<90 days) after surgery and did not appear to increase further with longer duration of the study. Myocardial fibrosis was reported only after 90
Table 3 Models of combined volume and pressure overload

<table>
<thead>
<tr>
<th>Method</th>
<th>Strengths</th>
<th>Limitations</th>
<th>Mouse</th>
<th>Rat</th>
<th>Rabbit</th>
<th>Dog</th>
<th>Sheep</th>
<th>Pig</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Volume load + pulmonary hypertension</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MCT + shunt</td>
<td>Vascular remodeling comparable to human PAH</td>
<td>Rapid RV decompensation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Time dependent progression of severe RV failure</td>
<td>Possible direct effects of MCT on the RV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic arterial-venous shunting</td>
<td>Physiology highly similar to PAH in adult ASD patients</td>
<td>Mild pulmonary hypertension</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;6 months to develop pressure load</td>
<td>Shunt induced after birth</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fetal aorto-pulmonary shunt</td>
<td>Mimics pathophysiology of congenital shunts</td>
<td>Technically challenging surgical model</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Only mild PAH and RV dysfunction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Volume load + pulmonary artery banding</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shunt + pulmonary artery banding</td>
<td>Precise volume and afterload increase</td>
<td>Need for open chest</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stable afterload, Adjustable</td>
<td>Only one study (in dogs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Wide range of RV strain</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary regurgitation + pulmonary artery banding</td>
<td>Physiology similar to patients with tetralogy of Fallot</td>
<td>Difficult</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Need for open chest</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Only one study (in pigs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

An overview of models of Models of combined volume and pressure overload stratified to method of combined load increase and animal species. PAH, pulmonary arterial hypertension; MCT, monocrotaline.

days of volume overload (135).

**Combined volume- and pressure overload-induced RV failure**

A typical clinical example of combined RV volume and pressure overload can be found in patients with PAH due to a congenital cardiac left-to-right shunt (PAH-CHD). In these patients, the volume load is congenital and pressure load develops progressively due to increasing PVR as a result of pulmonary vascular remodeling (134). Although PAH is primarily a disease of the pulmonary vasculature, the state of the RV is the main determinant of survival (165). In PAH patients both with and without a shunt, the severity of RV failure is determined primarily by the degree of pressure overload and has been correlated closely to PVR (165). The contribution to RV failure of the additional volume overload component in shunt-associated PAH is considerably less studied (137). During pressure load, increased preload may help to maintain adequate stroke volume via the Frank-Starling mechanism (79). However, combined loading conditions have also been associated with worse RV function and outcome in chronic settings (137). An alternative example of combined volume and pressure load is found in patients with repaired ToF, who often have residual pulmonary regurgitation as well as pulmonary branch stenosis: a combination that frequently leads to RV failure (74). Animal models for combined RV volume and pressure overload that mimic the conditions above can be categorized as: (I) shunt + PH induced by MCT or chronic overcirculation (PH), (II) shunt + PAB and (III) pulmonary regurgitation + PAB. The available models are listed in Table 2 and reviewed below.
Shunt + PH

**Aorto-caval shunt + monocrotaline**

The MCT+ aorto-caval Shunt model in rats was originally developed as a ‘double hit’ alternative to the MCT-only model. MCT-only rats lack so-called neointimal pulmonary vascular lesions that are characteristic of severe group 1 PAH (156,166). It was demonstrated that the addition of increased pulmonary blood flow to MCT does lead to neointimal lesions and a more severe, progressive form of PAH (81,167), making it more relevant to human PAH. The MCT + Shunt model in rats combines a 60 mg/kg injection of monocrotalin at day 0 with the surgical construction of an aorto-caval shunt at day 7 (139). The shunt is created by inserting an 18G needle from the abdominal aorta into the adjacent caval vein, leading to pulmonary overcirculation and RV volume overload. The combination of MCT and the shunt leads to neomuscularization of the pulmonary arterioles at day 14, the formation of occlusive neointimal lesions from day 21, and RV failure around day 28, followed by death from day 28 to 35 (138-140). The shunt increases RV cardiac output two-to-three fold, as well as TAPSE. From day 21, occlusive vascular remodeling causes the PVR to rise, resulting in an increase in systolic RVP up to 60mmHg and a decrease in pulmonary artery acceleration time. From day 21–35 TAPSE and cardiac output decrease progressively and RV hypertrophy occurs (138-140). The MCT + Shunt model has been implemented primarily to investigate new treatment strategies for pulmonary vascular disease, but can also be used to study combined volume and pressure overload of the RV, especially when PAB-, MCT- or Shunt-only rats are used additionally as a control or to compare different loading conditions (137,141). In a direct comparison with MCT-only or Shunt-only, MCT + Shunt results in a significantly compromised RV contractility, worse RV diastolic function, increased RV hypertrophy and more clinical signs of RV failure. Combined overload also had a strong additive effect on MYH-isoform switch, associated with pathologic RV remodeling (137).

**Chronic shunting models**

Chronic shunting leads to RV volume overload and secondary pulmonary hypertension, albeit mild. After 20 weeks, adult rats with an aorto-caval shunt show an increase in mPAP up to 40mmHg indicating increased afterload. Parameters for RV systolic and diastolic function, such as dP/dtMAX, PRSW, and Tau were also decreased after 20 weeks, but symptoms of RV failure were not observed (144). Aorto-caval shunt in pigs leads to an increase in mPAP from 10 to 15mmHg after 5 weeks (145). The pulmonary vascular histology in chronic shunting adult animals is characterized by mild medial hypertrophy, resembling an early, reversible stage of PAH associated with pre-tricuspid shunts (134,144).

**Fetal aorto-pulmonary shunt**

An in utero aorto-pulmonary shunt model in lambs induces chronic overflow through the pulmonary vascular bed mimicking the induction of PAH seen in several congenital heart conditions (146). This induces hyperproliferation of the pulmonary artery smooth muscle cells (147), alters the redox environment (168), induces vascular dysfunction independently of the NO-cGMP pathway (148), and induces sustained increase in pulmonary artery resistance (146). The phenotype in this model is mild PAH and RV dysfunction, but it is a solid animal model for investigating the mechanisms involved in congenital overflow induced PAH (149-151,169,170).

**Shunt + PAB**

One study in dogs induced chronic RV volume overload by a bifemoral arteriovenous shunt. The shunts were closed after 3 months and then RV pressure load was created by PAB. The arteriovenous shunts increased cardiac output by 30%, and RVSP from 25 to 34 mmHg, but RV systolic or diastolic function were not changed compared to non-shunted controls (152). Both shunted and non-shunted dogs were able to sustain a stable cardiac output after PAB. However, non-shunted controls responded to PAB by increasing contractility, whereas in shunted dogs contractility did not increase and cardiac output relied on the Frank-Starling mechanism as a primary adaptation to increased afterload.

**Pulmonary regurgitation + PAB**

In pigs, a combination of RV tract enlargement by transvalvular patch (volume overload via pulmonary regurgitation) and PAB, induced an increase in RV peak pressure to around 60 mmHg after 4 months, compared to 16 mmHg in non-operated controls. End-systolic and end-diastolic volumes were higher and ejection fraction was lower in operated pigs. These hemodynamic changes were also associated with cardiac fibrosis myocyte hypertrophy and inflammation (74).

**Other genetic models of PAH and RV dysfunction**

Intriguing genetic models have increased our knowledge about important pathophysiological mechanisms in
the development of RV failure and PH (171) including bone morphogenetic peptide receptor type 2 (BMPR-2) knockout mice (172), low-density lipoprotein receptor–related protein 1 (LRP1) deficient mice (173), and insulin-resistant male apoE-deficient mice (174). TGF-β1 transgenic mice with heightened level of circulating TGF-β1 show pulmonary vascular remodeling and increased RV pressure in room air (175), and stimulation of the peroxisome proliferator-activated receptor gamma (PPARγ) by oral pioglitazone downstream of the BMP2 receptor reversed PH in these TGF-β1 transgenic mice. In this work, PPARγ has been identified as a link between the anti-proliferative BMP2 and the proliferative TGF-β signaling pathways in vascular SMC known to be dysbalanced in human PAH (175).

Mice with targeted deletion of PPARγ in smooth muscle cells spontaneously developed PAH (176). Moreover, selective deletion of PPARγ in cardiomyocytes leads to biventricular systolic dysfunction in mice underlining the central beneficial role of PPARγ not only in PH lungs but also RV dysfunction (110,177).

**Future directions**

There is a plethora of animals models of acute and chronic-progressive RV dysfunction and failure. To ensure the best translation from bench to bedside we advocate that the researcher carefully select the animal model that is best suited to the research question at hand. In this review we present the available animal models for RV failure. We do, however, still need to refine and develop animal models of RV failure to create more precise pathophysiologic- and biologic modeling to ensure the best possible pre-clinical research and successful clinical translation (178-181).

**Acknowledgments**

**Funding:** None.

**Footnote**

*Provenance and Peer Review:* This article was commissioned by the Guest Editors (Martin Koestenberger, Harm-Jan Bogaard and Georg Hansmann) for the series “Right Ventricular Dysfunction” published in *Cardiovascular Diagnosis and Therapy*. The article was sent for external peer review organized by the Editor-in-Chief and the editorial office.

**Conflicts of Interest:** All authors have completed the ICMJE uniform disclosure form (available at [http://dx.doi.org/10.21037/cdt-20-400](http://dx.doi.org/10.21037/cdt-20-400)). The series “Right Ventricular Dysfunction” was commissioned by the editorial office without any funding or sponsorship. GH and HJB served as the unpaid Guest Editors of the series. AA reports grants from Alfred Benzons Foundation, outside the submitted work. GH reports grants from German Research Foundation (DFG; HA4348/2-2 and HA4348/6-2 KFO311), grants from the Federal Ministry of Education and Research (BMBF ViP+ program-03VP08053; BMBF 01KC2001B), grants from the European Pediatric Pulmonary Vascular Disease Network ([www.pvdnetwork.org](http://www.pvdnetwork.org)), outside the submitted work. HJB reports grants from Dutch Cardiovascular Research Alliance, from null, outside the submitted work. The authors have no other conflicts of interest to declare.

**Ethical Statement:** The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Open Access Statement:** This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: [https://creativecommons.org/licenses/by-nc-nd/4.0/](https://creativecommons.org/licenses/by-nc-nd/4.0/).

**References**


